6,150 AbbVie Inc. $ABBV Shares Sold by Yousif Capital Management LLC

Key Points

• Yousif Capital Management reduced its AbbVie stake by 3%, selling 6,150 shares and retaining 196,219 shares worth approximately $51.3 million. Institutional investors and hedge funds collectively own 70.23% of AbbVie.
• Analysts maintain a favorable outlook, with a consensus rating of “Moderate Buy” and an average price target of $279.86. Recent target increases range from $260 to $320.
• AbbVie reported quarterly revenue of $16.99 billion and EPS of $3.65, beating estimates, while declaring a quarterly dividend of $1.73. Growth from SKYRIZI and RINVOQ is supporting the company’s post-Humira strategy, though investors remain cautious ahead of earnings due to the stock’s premium valuation.

Yousif Capital Management LLC lessened its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 3.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 196,219 shares of the company's stock after selling 6,150 shares during the period. AbbVie comprises about 0.6% of Yousif Capital Management LLC's investment portfolio, making the stock its 24th largest position. Yousif Capital Management LLC's holdings in AbbVie were worth $51,329,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the stock. State Street Corp increased its position in shares of AbbVie by 1.7% in the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company's stock worth $20,784,646,000 after purchasing an additional 1,379,232 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of AbbVie by 0.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company's stock worth $3,590,323,000 after purchasing an additional 106,091 shares during the last quarter. Legal & General Group Plc bought a new position in shares of AbbVie during the second quarter worth about $2,905,952,000. Deutsche Bank AG grew its stake in AbbVie by 13.0% in the second quarter. Deutsche Bank AG now owns 10,772,949 shares of the company's stock worth $2,710,905,000 after purchasing an additional 1,241,587 shares in the last quarter. Finally, Amundi grew its stake in AbbVie by 2.4% in the first quarter. Amundi now owns 10,698,095 shares of the company's stock worth $2,326,728,000 after purchasing an additional 247,689 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business's stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

ABBV has been the subject of several research analyst reports. Scotiabank boosted their price objective on AbbVie from $280.00 to $320.00 and gave the company an "outperform" rating in a report on Tuesday, October 6th. Citigroup increased their target price on AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a report on Wednesday, July 15th. Wells Fargo & Company increased their target price on AbbVie from $295.00 to $300.00 and gave the stock an "overweight" rating in a report on Monday, August 17th. Piper Sandler lifted their target price on AbbVie from $298.00 to $303.00 and gave the stock an "overweight" rating in a research report on Thursday, August 20th. Finally, HSBC boosted their price target on AbbVie from $300.00 to $315.00 and gave the company a "buy" rating in a report on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $279.86.

AbbVie Stock Performance

AbbVie stock opened at $285.66 on Friday. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $291.40. The firm's 50-day moving average is $266.33 and its 200-day moving average is $241.77. The company has a market cap of $504.70 billion, a P/E ratio of 80.69, a PEG ratio of 1.30 and a beta of 0.24.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter in the prior year, the firm earned $2.97 EPS. The company's revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts predict that AbbVie Inc. will post 13.93 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. AbbVie's dividend payout ratio (DPR) is 195.48%.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. FDA approved a subcutaneous induction regimen for SKYRIZI in adults with moderately to severely active Crohn’s disease. The on-body injector provides a more convenient administration option throughout treatment, while Phase 3 data showed superior clinical remission and endoscopic response versus placebo with no new safety risks. The approval could strengthen SKYRIZI’s commercial position and support AbbVie’s post-Humira growth strategy. FDA approves subcutaneous SKYRIZI induction for Crohn’s disease
• Positive Sentiment: AbbVie’s dividend remains a key defensive attraction. Analysts and financial commentators point to the company’s ability to maintain shareholder payouts despite Humira’s patent loss, supported by growth from SKYRIZI, RINVOQ and other newer products. AbbVie’s dividend after Humira’s patent cliff
• Neutral Sentiment: AbbVie’s Phase 3 INTREPID trial for lutikizumab in hidradenitis suppurativa met its primary endpoint and eight ranked secondary endpoints, including reduced pain and fewer flares. However, reported efficacy was viewed by some analysts as underwhelming relative to competing treatments, leaving the drug’s eventual commercial opportunity uncertain. AbbVie reports Phase 3 INTREPID results for lutikizumab
• Negative Sentiment: Investors are approaching next week’s earnings report cautiously. Erste Group lowered its 2026 EPS estimate to $13.90 from $14.00, slightly below the roughly $13.94 consensus, while a Zacks preview said AbbVie lacks the usual indicators for a likely earnings beat. With the shares trading near their 52-week high and at a premium valuation, results and guidance may need to be strong to sustain momentum. AbbVie earnings preview

AbbVie Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.